Clinically, the presence of CD36+ metastasis-initiating cells correlates with a poor prognosis for different carcinomas, and inhibition of CD36 also affects metastasis, at least in human melanoma- and breast cancer-derived tumors. Here, CD36 is linked to melanoma.